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Internal mammary lymph node (IMLN) biopsy for staging breast
cancer is not standard practice. The signiﬁcance of IMLNs encoun-
tered incidentally during dissection of internal mammary vessels
(IMVs) for microvascular free ﬂap breast reconstruction (FFBR) re-
mains obscure. Since our last study,1 we now routinely harvest inci-
dental IMLNs during FFBR. We present our 15-year experience with
the opportunistic harvest of IMLNs during FFBR.
All IMV anastomoses performed between 1997 and 2011 for
delayed (DBR) or immediate breast reconstruction (IBR) at Adden-
brooke’s University Hospital, Cambridge were identiﬁed from our
audit database. All IMLN harvests were analysed from our histology
database by retrospectively correlating them with patient and
tumour characteristics and oncological outcomes. Patients with
breast tumours that were large (T3), locally advanced (T4) or had
involvement of more than four axillary lymph nodes underwent
preoperative staging. This was performed with CT chest, abdomen
and pelvis with bone windows to include the upper femurs. Axil-
lary staging prior to 2006 involved level 2 axillary lymph node
dissection for invasive cancers and since then, sentinel lymph
node biopsy has been used.
A total of 503 FFBRs were performed in 474 patients. Of these, 86
patients (18%) had 95 IMLNs harvested during 54 immediate and 41
delayed FFBRs. Eleven patients (13%) had tumour-positive nodes
(Table 1, Fig. 1). In the IBR group, 7 of 44 patients were conﬁrmed
to have IMLN metastases histologically (16%) compared to 4 of 42
patients (10%) in the DBR group. The mean patient agewas 47 years
with no signiﬁcant age difference between the IBR and DBR groups.
Therewere also no signiﬁcantmacroscopic differences between the
metastatic and non-involved nodes. In the DBR group, the median
time between mastectomy and reconstruction was 30 months
(range 11–154).
All patients with positive IMLNs were offered chemotherapy
and eight received radiotherapy to the internal mammary chain.
Three of the seven IMLN positive IBR patients (43%) have died ofof Distinction” at the Society
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iates Ltd. Published by Elsevier Ltic disease at 23, 33 and 55 months after reconstruction.
IMLN positive DBR patients are alive at 18, 22, 40 and 58
months.epidermal growth factor receptor 2, IDC – inﬁltrating ductal carcinoma, ILC – inﬁl-
trating lobular carcinoma, LVI – lymphovascular invasion, LOQ – lower outer quad-
rant, OQ – outer quadrants, PR – progesterone receptor, SLNBx – sentinel lymph
node biopsy, TRAM – transverse rectus abdominis myocutaneous, UIQ – upper inner
quadrant, UOQ – upper outer quadrant.
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Fig. 1. Outcomes of opportunistic harvest of internal mammary lymph nodes (IMLNs)
in patients undergoing free ﬂap delayed (DBR) and immediate breast reconstruction
(IBR).
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LETTER TO THE EDITORThe incidental ﬁnding of IMLN metastasis signiﬁcantly altered
themanagement of three delayed reconstruction patients including
upstaging of one patient in whom axillary nodal staging was not
possible due to previous axillary dissection. One received both
chemotherapy and radiotherapy, one received chemotherapy alone
and the other, endocrine therapy alone. Management was also
signiﬁcantly altered for one immediate reconstruction patient
who received chemotherapy as a result of the positive IMLN biopsy.
In our study, patients with positive IMLNs in the IBR group seem to
carry aworse prognosis than the DBR group as the only deaths were
in the former group.
IMLNmetastasis is well known as a poor prognostic indicator in
breast cancer. There continues to be discussion on whether to
perform routine IMLN biopsy.2,3 Although routine IMLN biopsy
does not appear to improve survival,3,4 IMLN status can provide
useful additional staging information and help prevent patients
from being under-staged. Furthermore, radiotherapy may improve
local disease control for positive IMLNs and thus prolong the
disease-free interval or overall survival.5
We believe that any obvious IMLNs seen during IMV dissection
for FFBR should be routinely biopsied. We are not advocating elec-
tive dissection of IMLNs as this has not been addressed in this study.
Opportunistic biopsy can be achieved with minimal additional
morbidity and results can inﬂuence subsequent management and
predicted prognosis.
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